Anúncio
Anúncio

BOLT

BOLT logo

Bolt Biotherapeutics, Inc. Common Stock

5.83
USD
Patrocinado
+0.02
+0.34%
09 de jan., 15:58 UTC -5
Encerrado
exchange

Pós-Mercado

5.64

-0.19
-3.26%

Relatórios de Lucros BOLT

Rácio de surpresa positiva

BOLT separação 15 de 20 últimas estimativas.

75%

Próximo Relatório

Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$680.00K
/
-$6.22
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-68.65%
/
+67.20%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-18.16%

Bolt Biotherapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, BOLT reported earnings of -3.72 USD per share (EPS) for Q3 25, beating the estimate of -5.90 USD, resulting in a 36.99% surprise. Revenue reached 2.17 milhão, compared to an expected 739.50 mil, with a 193.31% difference. The market reacted with a +0.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of -6.22 USD, with revenue projected to reach 680.00 mil USD, implying an aumentar of 67.20% EPS, and diminuir of -68.65% in Revenue from the last quarter.
FAQ
For Q3 2025, Bolt Biotherapeutics, Inc. Common Stock reported EPS of -$3.72, beating estimates by 36.99%, and revenue of $2.17M, 193.31% above expectations.
The stock price moved up 0.21%, changed from $4.69 before the earnings release to $4.70 the day after.
The next earning report is scheduled for 23 de mar. de 2026.
Based on 7 analistas, Bolt Biotherapeutics, Inc. Common Stock is expected to report EPS of -$6.22 and revenue of $680.00K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio